Oppenheimer raised the price target for the Ascendis Pharma A/S (NASDAQ:ASND) stock from “an Outperform” to “a Perform”. The rating was released on March 30, 2021. The research report from Berenberg has initiated the stock to Buy, with a price target set at $216. The stock was resumed by JP Morgan, who disclosed in a research note on September 14, 2020, to Overweight and set the price objective to $160. In their research brief published March 20, 2020, Oppenheimer analysts initiated the Ascendis Pharma A/S stock to Outperform with a price target of $199.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Ascendis Pharma A/S (NASDAQ:ASND) raised 21.05% to close Thursday’s market session at $149.70, higher as compared to yesterday’s close. The stock price fluctuated between $146.09 and $158.78 throughout the trading session with the volume trading being 2228193 shares, which represented a significant variation when compared to the three months average volume of 198.48K shares. The firm’s stock price fluctuated 25.71% within the last five trades and 29.15% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -3.40% in the last 6 months and 9.92% was added to its value over the previous 3 months. ASND stock is trading at a margin of 23.30%, 19.20% and 4.51% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ASND deals in the Healthcare domain. The stock is trading -18.63 percent below its 52-week high and 36.89 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 2.63. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Ascendis Pharma A/S’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $7.97 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1244.85 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 8.59, which equates the market value of a stock with its book value.